Shareholders Approve Significant Expansion of Equity Incentive Plan, Authorizing 11M New Shares

summarizeSummary

Vivani Medical shareholders approved a significant expansion of the equity incentive plan, authorizing 11 million new shares, while the company also received regulatory approval to initiate a Phase 1 clinical trial for its semaglutide implant.

check_boxKey Events · Corporate Governance and Compliance · VANI

• Equity Incentive Plan Expanded

  Shareholders approved an amendment to the 2022 Omnibus Incentive Plan, increasing the number of shares reserved for issuance by 11,000,000, from 10,033,333 to 21,033,333 shares. This represents a potential dilution of approximately 12.76% based on current outstanding shares.

• Regulatory Approval for Phase 1 Clinical Trial

  The company received regulatory approval from Bellberry (Australia) to initiate SLIM-1, a Phase 1 clinical trial for its NPM-139 semaglutide implant in obesity and chronic weight management. This news was previously announced via press release on June 25, 2026.

• Director Re-election Confirmed

  All six director nominees, including active insider Gregg Williams, were re-elected to the Board during the Annual Meeting held on June 24, 2026.

auto_awesomeAnalysis · VANI · Industrial Applications And Services

Shareholders approved an amendment to the 2022 Omnibus Incentive Plan, increasing the number of shares reserved for issuance by 11,000,000. This represents a potential dilution of approximately 12.76% if all authorized shares were issued, creating an overhang for existing shareholders. This approval finalizes a proposal previously disclosed in the DEF 14A filing on April 29, 2026. Additionally, the company announced regulatory approval to initiate the SLIM-1 Phase 1 clinical trial for its NPM-139 semaglutide implant in obesity, a positive development for its product pipeline, though this news was previously announced via press release on June 25, 2026.